α-Glucosidase-IN-15 (Compound 14B) exhibits potent inhibitory activity against α-glucosidase, with an IC50 value of 3.34 μM. It possesses antidiabetic properties [1].

α-Glucosidase-IN-15 (Compound 14B) (10 and 20 mg/kg; p.o.; b.w. for 4 weeks) shows antidiabetic activity in Streptozocin -induced diabetic rats [1]. α-Glucosidase-IN-15 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats [1]. α-Glucosidase-IN-15 (2000mg/kg; p.o.; b.w. for 2 weeks) demonstrates no mortality in mice [1]. Animal Model: Male Wistar albino rats (170–200 g), Streptozotocin-induced diabetes model [1] Dosage: 10 and 20 mg/kg Administration: Oral administration, b.w. for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers.